2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human microvascular retinal endothelial cells

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3677
    Dammarenediol II

    		OGT Akt mTOR GSK-3 Reactive Oxygen Species (ROS) Apoptosis PARP MDM-2/p53 Inflammation/Immunology Cancer
    Dammarenediol II is a ginsenoside precursor . Dammarenediol II reduces the activity of O-GlcNAc transferase (OGT) and downregulates the global O-GlcNAcylation level. Dammarenediol II inhibits the phosphorylation of Akt, mTOR and GSK3β. Dammarenediol II inhibits human carboxylesterase activity, VEGF-induced ROS production, stress fiber formation and vascular endothelial cadherin disruption. Dammarenediol II promotes cell apoptosis (apoptosis), increases the levels of cleaved PARP1 and p53, and inhibits retinal microvascular leakage. Dammarenediol II can be used in studies related to liver cancer and diabetic retinopathy .
    Dammarenediol II
  • HY-N8178
    (R)-(4′-Hydroxy)-5,7-dihydroxy-4-chromanone

    		Others Cardiovascular Disease
    (R)-(4′-Hydroxy)-5,7-dihydroxy-4-chromanone, a homoisoflavonoid, has antiangiogenic activity against human retinal microvascular endothelial cells .
    (R)-(4′-Hydroxy)-5,7-dihydroxy-4-chromanone
  • HY-159962
    TGase2-IN-1

    		Glutaminase Metabolic Disease
    TGase2-IN-1 (Compound 22) is an orally active inhibitor for TGase2 with an IC50 of 1.12 μM. TGase2-IN-1 inhibits TGase2 in human retinal microvascular endothelial cells with an IC50 of 0.07 μM. TGase2-IN-1 exhibits 74.6% oral bioavailability. TGase2-IN-1 inhibits retinal vascular leakage in mouse Streptozotocin (HY-13753)-induced diabetic model .
    TGase2-IN-1
  • HY-120267
    TID43

    		Casein Kinase Cardiovascular Disease
    TID43 is a CK2 inhibitor, with an IC50 of 0.3 μM. TID43 can be used for anti-angiogenic research .
    TID43
  • HY-182372
    SH-11037

    		Epoxide Hydrolase Neurological Disease
    SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization .
    SH-11037

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: